← All trials
NCT06616441
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2023
- Primary completion
- Sep 15, 2024
- Completion date
- Sep 15, 2024
- First posted
- Sep 27, 2024
- Last posted
- Sep 27, 2024
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- El Shatby University Hospital for Obstetrics and GynecologyLead sponsor
- El Shatby University Hospital for Obstetrics and GynecologySponsor investigator
- Alexandria UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.